Recombinant human C1 esterase inhibitor (conestat alfa) in the prevention of severe SARS-CoV-2 infection in hospitalized patients with COVID-19: A structured summary of a study protocol for a randomized, parallel-group, open-label, multi-center pilot trial (PROTECT-COVID-19)
입원한 COVID-19 환자의 중증 SARS-CoV-2 감염 예방을 위한 재조합 인간 C1 에스테라제 억제제(conestat alfa): 무작위, 병렬 그룹, 공개 라벨, 다중 센터에 대한 연구 프로토콜의 구조화된 요약 파일럿 시험(PROTECT-COVID-19)
Letter
[키워드] 24 hour
24 hours
Activation
activities
acute lung injury
addition
adjusted
Administered
administration
allergy
Antibiotics
anticipated
anticoagulation
arterial
Arterial hypertension
Basel
Blinding
BMI
Brazil
Breast
Breast feeding
breathing ambient air
C-reactive protein
C1 esterase inhibitor
cardiovascular disease
Caregivers
changes in
Chest
Child-Pugh score
chronic
chronic pulmonary disease
chronic renal disease
cirrhosis
class
clinical
Clinical improvement
clinical trial
comparator
comparator Patients
complement
complement system
completion
conducted
Conestat alfa
Contact
contact activation system
contraindication
control group
Corticosteroids
COVID-19
COVID-19 patient
CT scan
death
defined
discharge
disease
disease severity
dissemination
drug
Duration
Efficacy and safety
element
eligibility
enrolment
evidence of
experimental arm
family members
FIVE
followed by
history
hospital
Hospitalization
hospitalized patient
hypertension
ICU
IL-6 inhibitor
IL-6R
improvement
Incapacity
include
inclusion criteria
individual
Infection
inflammatory cascade
inflammatory cascades
inflammatory proteins
inhibitor
Interactive Web Response System
interim analysis
Intravenous injection
invasive
invasive or non-invasive ventilation
investigator-initiated
investigators
kallikrein kinin system
laboratory parameter
Liver cirrhosis
Local
Lung injury
mechanical ventilation
non-invasive ventilation
not blinded
number
obesity
objective
Open-label
open-label trial
Ordinal Scale
outcome
outcome assessor
outcome assessors
oxygen
oxygen saturation
pandemic
PaO
parallel-group
participant
Participants
Participation
Patient
performed
Pregnancy
primary endpoint
progression
proportion
protocol
pulmonary disease
pulmonary involvement
randomised
randomization
Randomized
randomized trial
receive
recombinant
recruited
recruitment
Registered
Remdesivir
renal
renal disease
required
risk factor
Sample size
SARS-COV-2 infection
SARS-CoV-2 pandemic
scale
screened
secondary
Secondary outcomes
severe COVID-19
severe SARS-CoV-2
Standard of care
status
Study protocol
subject
supplemental oxygen
supplementary material
suspicion
Switzerland
Symptom
the SARS-CoV-2
the WHO
their family members
Tocilizumab
Treatment
treatment arm
Trial
Two interim analyses
Two interim analysis
virological clearance
website
WHO
WHO ordinal scale
with COVID-19
X-ray
[DOI] 10.1186/s13063-020-04976-x PMC 바로가기 [Article Type] Letter
[DOI] 10.1186/s13063-020-04976-x PMC 바로가기 [Article Type] Letter